Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Neogenomics Inc (NEO) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 659,510
  • Shares Outstanding, K 77,890
  • Annual Sales, $ 99,800 K
  • Annual Income, $ -2,540 K
  • 36-Month Beta 1.05
  • Price/Sales 3.13
  • Price/Book 3.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.01 +4.74%
on 01/12/17
9.69 -13.42%
on 12/21/16
-1.11 (-11.68%)
since 12/16/16
3-Month
6.90 +21.59%
on 10/26/16
9.88 -15.08%
on 12/13/16
+0.88 (+11.72%)
since 10/17/16
52-Week
5.49 +52.82%
on 02/12/16
9.88 -15.08%
on 12/13/16
+1.36 (+19.35%)
since 01/15/16

Most Recent Stories

More News
NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2016.

Investor Calendar Invites You to the NeoGenomics Third Quarter 2016 Earnings Conference Call and Webcast Live on Wednesday, October 26, 2016

FORT MYERS, FL / ACCESSWIRE / October 25, 2016 / NeoGenomics, Inc. (NASDAQ: NEO) will host a conference call and live webcast to discuss the results of the third quarter 2016, to be held Wednesday, October...

Healthcare Stocks on Investors' Radar -- Exact Sciences, Great Basin Scientific, Agilent Technologies, and Neogenomics

On Wednesday, the US markets continues on the previous day's bullish trend as the NASDAQ Composite ended the trading session up 0.05%; the Dow Jones Industrial Average edged 0.22% higher; and the S&P 500...

NeoGenomics Schedules its Q3 2016 Earnings Release for October 26, 2016

NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its third quarter 2016 financial results on Wednesday October 26, 2016.

Health Discovery Corporation Forms Development Committee

Health Discovery Corporation ("HDC" or the "Company"), an intellectual property development company using patent protected advanced mathematical techniques for personalized medicine, announced...

How These Healthcare Stocks are Performing? -- AMAG Pharma, IDEXX Laboratories, Neogenomics, and ICON

The Healthcare sector remains one of the most stable industries in the market, unfazed by economic conditions and uncertainties. While the industry faces issues with cost pressures, ransomware risks, and...

Pressure BioSciences' SCIEX Deal Could Dramatically Accelerate Revenue

REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), recently announced...

NeoGenomics Schedules its Q4 2015 and full year 2015 Earnings Release for March 1, 2016

NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter 2015 and full year 2015 financial results on Tuesday, March 1, 2016.

Healthcare Sector Stocks Technical Coverage -- Neogenomics, OraSure Technologies, Tetraphase Pharma, and LeMaitre Vascular

NEW YORK, NY / ACCESSWIRE / January 14, 2016 / Park Lane Advisor has initiated coverage on the following equities: Neogenomics Inc. (NASDAQ: NEO), OraSure Technologies Inc. (NASDAQ: OSUR), Tetraphase Pharmaceuticals...

Dycom & 4 Other Surprise Champions of 2015

Prepare your portfolio with these surprise winners of 2015 that look set to win in 2016 as well.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Support & Resistance

2nd Resistance Point 8.64
1st Resistance Point 8.51
Last Price 8.39
1st Support Level 8.28
2nd Support Level 8.18

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.